


REMARKS

Entry of the foregoing amendment is requested. Prompt examination is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By: 

Norman D. Hanson, Esq.

Registration No. 30,946

666 Fifth Avenue

New York, New York 10103-3198

(212) 318-3000

(212) 318-3400 (fax)

Page 18, lines 8-11, delete and replace by the following:

~~The peptides may be combined with peptides from other tumor rejection antigens to form ‘polytopes’. Exemplary peptides include those listed in U.S. Patent Application Serial Numbers 08/672,351, 08/718,964, now U.S. Patent No. _____, 08/487,135 now U.S. Patent No. 08/530,569 and 08/880,963 all of which are incorporated by reference. The peptides may be combined with peptides that are other tumor rejection antigens to form “polytopes.” Exemplary peptides include those listed in U.S. Patent Application Serial Numbers 08/672,351, 08/718,964, now U.S. Patent No. 5,932,694, 08/487,135 now U.S. Patent No. 5,821,122, 08/530,569 and 08/880,963, all of which are incorporated by reference.~~

Page 8, lines 6-13, replace with the following:

TABLE 1

Peptide	Sequence	Relative competitor activity
<u>Influenza A matrix</u>		
58-66	GILGFVFTL	1
<u>NY-ESO-1:</u>		
155-163	QLSLLMWIT	0.01
157-167	SLLMWITQCFL	0.04
157-165	SLLMWITQC	0.004
157-C165A	SLLMWITQA	0.4
157-C165L	SLLMWITQL	0.5
157-C165V	SLLMWITQV	10
<u>Influenza A matrix</u>		
<u>58-66</u>	<u>GILGFVFTL (SEQ ID NO: 5)</u>	<u>1</u>
<u>NY-ESO-1:</u>		
<u>155-163</u>	<u>QLSLLMWIT (SEQ ID NO: 3)</u>	<u>0.01</u>
<u>157-167</u>	<u>SLLMWITQCFL (SEQ ID NO: 1)</u>	<u>0.04</u>
<u>157-165</u>	<u>SLLMWITQC (SEQ ID NO: 2)</u>	<u>0.004</u>
<u>157-C165A</u>	<u>SLLMWITQA (SEQ ID NO: 6)</u>	<u>0.4</u>
<u>157-C165L</u>	<u>SLLMWITQL (SEQ ID NO: 7)</u>	<u>0.5</u>
<u>157-C165V</u>	<u>SLLMWITQV (SEQ ID NO: 8)</u>	<u>10</u>